Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Subscribe To Our Newsletter & Stay Updated
